Research Blog
Latest Articles
Evidence-based guides on research peptides, vendor reviews, and buyer education.
Cagrilintide: The Complete Research Guide
An amylin analog studied on its own and — more compellingly — alongside semaglutide, where combination data shows an effect neither compound produces by itself. Unlike semaglutide, no form of this compound has ever been FDA-approved.
Read article →
Retatrutide: The Complete Research Guide
The triple GIP/GLP-1/glucagon agonist with the strongest weight-loss data of any compound in its class — and a regulatory status well behind the science.
Read article →
Tirzepatide: The Complete Research Guide
The dual GIP/GLP-1 agonist behind Mounjaro and Zepbound — and the gap between the approved drug and what's actually sold as a research compound.
Read article →
Semaglutide: The Complete Research Guide
The GLP-1 agonist behind Ozempic and Wegovy has the deepest evidence base of any compound on the site — and the widest gap between the approved drug and what's actually sold as a research compound.
Read article →
Tesamorelin: The Complete Research Guide
A genuinely FDA-approved GHRH analogue — but the approval covers one narrow HIV-related indication, not general body composition. Here's exactly what it does and doesn't cover.
Read article →
AOD-9604: The Complete Research Guide
A growth-hormone fragment marketed on a mechanism its own foundational study didn't confirm — and the one time it was tested for its main proposed use in humans, it failed.
Read article →